Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial.
Fiche publication
Date publication
mars 2023
Journal
BMC cardiovascular disorders
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
H Brandt-Jacobsen N, Johansen ML, Rasmussen JJ, Dalsgaard M, Kumler T, Faber J, Rossignol P, Schou M, Kistorp C
Lien Pubmed
Résumé
Early heart failure prevention is central in patients with type 2 diabetes, and mineralocorticoid receptor antagonists (MRAs) have shown to improve prognosis. We investigated the effect of high-dose MRA, eplerenone, on cardiac function and structure in patients with type 2 diabetes and established or increased risk of cardiovascular disease but without heart failure.
Mots clés
Global longitudinal strain, High-dose eplerenone, Mineralocorticoid receptor antagonist, Systolic and diastolic function
Référence
BMC Cardiovasc Disord. 2023 03 31;23(1):175